MA38135B1 - Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium - Google Patents
Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calciumInfo
- Publication number
- MA38135B1 MA38135B1 MA38135A MA38135A MA38135B1 MA 38135 B1 MA38135 B1 MA 38135B1 MA 38135 A MA38135 A MA 38135A MA 38135 A MA38135 A MA 38135A MA 38135 B1 MA38135 B1 MA 38135B1
- Authority
- MA
- Morocco
- Prior art keywords
- calcium
- potassium channel
- channel inhibitors
- activated potassium
- oxazolidinone derivatives
- Prior art date
Links
- -1 3,4-disubstituted oxazolidinone Chemical class 0.000 title 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 title 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 | ||
| PCT/EP2013/072361 WO2014067861A1 (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38135A2 MA38135A2 (fr) | 2016-11-30 |
| MA38135B1 true MA38135B1 (fr) | 2018-11-30 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38135A MA38135B1 (fr) | 2012-10-29 | 2013-10-25 | Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium |
Country Status (23)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| JP7699820B2 (ja) | 2019-03-22 | 2025-06-30 | サニオナ エー／エス | 新規カリウムチャネル阻害剤 |
| CN116368112A (zh) * | 2020-09-22 | 2023-06-30 | 萨尼奥纳有限责任公司 | 新型钾通道抑制剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| DK429986A (da) * | 1985-09-09 | 1987-03-10 | Otsuka Pharma Co Ltd | 2-oxa-isocephemforbindelser |
| EP0557408A4 (en) * | 1990-11-06 | 1993-10-27 | Smith-Kline Beecham Corporation | Imidazolidinone compounds |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| AU1812197A (en) * | 1996-03-01 | 1997-09-16 | Sankyo Company Limited | Hydroxamic acid derivatives |
| NZ511334A (en) * | 1998-12-04 | 2003-06-30 | Neurosearch As | Benzimidazolone derivatives useful as ion channel modulating agents |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| RU2230060C2 (ru) * | 2000-01-20 | 2004-06-10 | Эйсай Ко., Лтд. | Соединения, фармацевтическая композиция, способ предотвращения гибели нервных клеток, способ профилактики |
| ES2231581T3 (es) * | 2000-11-22 | 2005-05-16 | Bayer Healthcare Ag | Nuevos derivados de pirazolopiridina sustituidos con lactama. |
| AU2005267884B2 (en) | 2004-07-29 | 2011-04-21 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| TW201026708A (en) | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en active Application Filing
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Withdrawn
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN00961A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-06-12 |
| IL237331A0 (en) | 2015-04-30 |
| SG11201500585XA (en) | 2015-04-29 |
| WO2014067861A1 (en) | 2014-05-08 |
| TW201422596A (zh) | 2014-06-16 |
| AU2013339607A1 (en) | 2015-02-05 |
| EP2912034B1 (en) | 2017-05-31 |
| HK1207632A1 (en) | 2016-02-05 |
| JP6216385B2 (ja) | 2017-10-18 |
| CR20150159A (es) | 2015-04-30 |
| BR112015003996A2 (pt) | 2017-07-04 |
| CL2015000906A1 (es) | 2015-09-11 |
| CO7170170A2 (es) | 2015-01-28 |
| EP2912034A1 (en) | 2015-09-02 |
| PH12015500292A1 (en) | 2015-04-20 |
| MX2015002399A (es) | 2015-06-10 |
| JP2015535231A (ja) | 2015-12-10 |
| EA026161B1 (ru) | 2017-03-31 |
| KR20150075091A (ko) | 2015-07-02 |
| US20150246894A1 (en) | 2015-09-03 |
| UA114649C2 (uk) | 2017-07-10 |
| EA201590729A1 (ru) | 2015-07-30 |
| AR093168A1 (es) | 2015-05-20 |
| CA2879249A1 (en) | 2014-05-08 |
| CN104781256A (zh) | 2015-07-15 |
| PE20150775A1 (es) | 2015-05-21 |
| US9611232B2 (en) | 2017-04-04 |
| MA38135A2 (fr) | 2016-11-30 |
| CN104781256B (zh) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37756A1 (fr) | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane | |
| MY155317A (en) | Benzene sulfonamide thiazole and oxazole compounds | |
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| ES2571489T3 (es) | Producto cosmético sólido para labios | |
| UY33750A (es) | ?Compuestos insecticidas aromáticos derivados de bisamida, procesos e intermediarios para prepararlos y composiciones que los usan.? | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| EP2694489A4 (en) | C5-C6-OXACYCLUS-Fused Thiadiazinyl-oxime Compounds as Bace Inhibitors, and Compositions Therefor, and Their Use | |
| MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
| MA38826B1 (fr) | Nouveaux dérivés de triazolo[4,5-d]pyrimidine | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
| MA34652B1 (fr) | Hétéroaryles et utilisations de ceux-ci | |
| WO2018136437A3 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| EP2400968A4 (en) | COMPOSITIONS, THEIR SYNTHESIS AND METHOD FOR THE USE OF ARYLPIPERAZINE DERIVATIVES | |
| UY33276A (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso | |
| MA32985B1 (fr) | Nouveaux microbiocides | |
| UA106880C2 (uk) | Нові гербіциди | |
| MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
| GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| MX358429B (es) | Nuevos derivados de isocromano e isotiocromano agonistas del adrenoreceptor alfa2a, especialmente agonistas del adrenoreceptor alfa2a para usarse como sedantes o analgesicos. | |
| DOP2013000063A (es) | Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación | |
| WO2013081778A3 (en) | Nitrone compounds for use as antioxidant in personal care | |
| MA38135A2 (fr) | Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium | |
| MA32717B1 (fr) | Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide | |
| CL2013003068A1 (es) | Compuestos derivados de 2-(etinil-piridin-2-il)-pirazolidin-3-ona, 2-(etinil-pirimidin-2-il)-pirazolidin-3-ona o 2-(etinil-piridazin-3-il)-pirazolidin-3-ona; moduladores alostericos positivos de mglur5; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar la esquizofrenia o enfermedades cognitivas. |